NCT07938073
Phase 2 Study Of IDH 1/2 Inhibitor Vorasidenib In Patients With IDH2-Mutated Intrahepatic Cholangiocarcinoma
StatusNot Yet Recruiting
PhasePhase 2
SponsorM.D. Anderson Cancer Center
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Safety and adverse events (AEs
Timeframe: Through study completion; an average of 1 year.
Arms and interventions
Safety Run-In/ExpansionExperimental
Treatment with Vorasidenib (PO) Q4W
Drugs: Vorasidenib
Sites
1 site in 1 country
- UT MD Anderson Cancer CenterHouston, Texas, United States